ARCT-165 / Arcturus Therap - LARVOL DELTA

A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=72 | Completed | Sponsor: Arcturus Therapeutics, Inc. | Recruiting ➔ Completed | Trial completion date: Mar 2023 ➔ Dec 2023 | Trial primary completion date: Mar 2023 ➔ Dec 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Vaccination of non-human primates with self-amplifying mRNA vaccines reveal two distinct immunotypes across major SARS-CoV-2 variants. (IMMUNOLOGY 2022) - P1/2 | "Arcturus Therapeutics has developed two low-dose, self-amplifying mRNA vaccines, ARCT-154 and ARCT-165, that elicits robust neutralizing antibodies in non-human primates (NHPs) as a primary vaccination series and as a booster vaccination to Comirnaty® in humans. However, in the context of a booster dose in humans (NCT05037097), ARCT-154 provides robust humoral responses across all variants tested. Next generation self-amplifying mRNA vaccines may provide better coverage and at booster doses that are 6-10 times lower than those of currently authorized mRNA vaccines."

Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases